DrugPatentWatch Database Preview
Lannett Co Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for LANNETT CO INC, and when can generic versions of LANNETT CO INC drugs launch?
LANNETT CO INC has one hundred and thirty-nine approved drugs.
There is one US patent protecting LANNETT CO INC drugs. There is one tentative approval on LANNETT CO INC drugs.
There are fifteen patent family members on LANNETT CO INC drugs in twelve countries and one hundred and twenty supplementary protection certificates in twelve countries.
Summary for Lannett Co Inc
| International Patents: | 15 |
| US Patents: | 1 |
| Tradenames: | 104 |
| Ingredients: | 97 |
| NDAs: | 139 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett Co Inc | OXYBUTYNIN CHLORIDE | oxybutynin chloride | SYRUP;ORAL | 076682-001 | Dec 28, 2004 | DISCN | No | No | Start Trial | Start Trial | |||||
| Lannett Co Inc | LETROZOLE | letrozole | TABLET;ORAL | 202048-001 | Oct 29, 2014 | DISCN | No | No | Start Trial | Start Trial | |||||
| Lannett Co Inc | BETHANECHOL CHLORIDE | bethanechol chloride | TABLET;ORAL | 040677-003 | Mar 27, 2008 | AA | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 091695-002 | Jul 9, 2013 | BX | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 091624-002 | Apr 5, 2013 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | MORPHINE SULFATE | morphine sulfate | SOLUTION;ORAL | 202309-001 | Nov 25, 2015 | DISCN | No | No | Start Trial | Start Trial | |||||
| Lannett Co Inc | BACLOFEN | baclofen | TABLET;ORAL | 077241-002 | Jul 6, 2007 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-002 | Jun 19, 2003 | 6,344,215 | Start Trial |
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-003 | May 27, 2003 | 6,344,215 | Start Trial |
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | Start Trial |
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-001 | Apr 3, 2001 | 6,344,215 | Start Trial |
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-004 | Feb 19, 2006 | 6,344,215 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
International Patents for Lannett Co Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1328251 | Start Trial |
| Spain | 2618603 | Start Trial |
| European Patent Office | 2103307 | Start Trial |
| Hungary | 0303695 | Start Trial |
| Australia | 2001297011 | Start Trial |
| Canada | 2426883 | Start Trial |
| European Patent Office | 2286815 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lannett Co Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1389098 | 300609 | Netherlands | Start Trial | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| 1411900 | 2011/016 | Ireland | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| 1441735 | 2008/010 | Ireland | Start Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220; |
| 0247633 | 97C0103 | Belgium | Start Trial | PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107 |
| 1685839 | 92292 | Luxembourg | Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| 0367141 | SPC/GB04/039 | United Kingdom | Start Trial | PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604 |
| 1507558 | 12C0033 | France | Start Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
